Literature DB >> 8389706

Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis.

D Gendrel1, J Raymond, M A Legall, M Bergeret, J Badoual.   

Abstract

Sixteen children (7 males, 9 females) aged 0.1 to 9.5 years (mean 3.6 years) who were hospitalized for severe salmonella infection were treated with conventional antibiotics. In nine children disappearance of fever and bloody diarrhea was obtained 2 to 4 days after the beginning of antibiotic therapy. Although the antibiotic administered was active against the pathogen, after 4 to 8 days the seven other children experienced clinical failure of the initial therapy, with a temperature of over 39 degrees C, bloody diarrhea and positive stool culture in all cases. The seven Salmonella strains isolated (1 S. typhi, 1 S. paratyphi B, 2 S. enteritidis, 3 S. typhimurium) were all sensitive to ampicillin, cotrimoxazole and pefloxacin. These seven children were then given 12 mg/kg/day of pefloxacin orally for 7 days. Apyrexia and complete resolution of diarrhea were obtained within 1 to 3 days in all cases without side effects. Trials are needed to determine the safety and toxicity of quinolones in children, however short-term therapy with pefloxacin could be useful in children with severe invasive salmonellosis after failure of conventional antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389706     DOI: 10.1007/bf01967114

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

Review 1.  Quinolone antibiotics in the treatment of Salmonella infections.

Authors:  M O Asperilla; R A Smego; L K Scott
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

2.  Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages.

Authors:  H R Chang; I R Vladoianu; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

Review 3.  Use of fluoroquinolones for intracellular pathogens.

Authors:  J J Pocidalo
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

4.  Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity.

Authors:  U B Schaad; J Wedgwood-Krucko
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

Review 5.  Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones.

Authors:  J P Bryan; H Rocha; W M Scheld
Journal:  Rev Infect Dis       Date:  1986 Mar-Apr

6.  Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin.

Authors:  U B Schaad; C Stoupis; J Wedgwood; H Tschaeppeler; P Vock
Journal:  Pediatr Infect Dis J       Date:  1991-10       Impact factor: 2.129

  6 in total
  4 in total

Review 1.  Fluoroquinolones in paediatrics.

Authors:  D Gendrel; F Moulin
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Quinolone use in the developing world: state of the art.

Authors:  T E Tupasi
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 3.  Fluoroquinolones in paediatrics--1995.

Authors:  R Dagan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Eradication of convalescent-phase Salmonella carriage in children with two oral doses of pefloxacin.

Authors:  J Raymond; F Moulin; J Badoual; D Gendrel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.